Related Experiment Videos
Bendectin (Debendox) as a risk factor for pyloric stenosis
American Journal of Obstetrics and Gynecology
|December 15, 1982
Summary
Maternal Bendectin (Debendox) use was linked to birth defects, particularly pyloric stenosis. Smoking amplified this risk, suggesting a complex relationship between medication, maternal factors, and infant congenital malformations.
Area of Science:
- Obstetrics and Gynecology
- Teratology
- Pediatric Epidemiology
Background:
- The safety of medications during pregnancy is a critical public health concern.
- Bendectin (Debendox) was a widely prescribed anti-nausea medication for pregnant women.
- Previous studies on Bendectin and birth defects yielded conflicting results.
Purpose of the Study:
- To investigate the association between maternal Bendectin use during the first trimester and the risk of congenital malformations in infants.
- To explore potential confounding factors, such as maternal smoking, in the Bendectin-birth defect relationship.
Main Methods:
- A case-control study design was employed.
- Data were collected from interviews with mothers of malformed infants (cases) and control infants.
- Sample size included 1,427 cases and 3,001 controls interviewed between 1974 and 1976.
Main Results:
- Mothers of infants with congenital malformations showed a higher likelihood of Bendectin use (odds ratio = 1.40).
- Bendectin use was more strongly associated with birth defects in mothers who also smoked (odds ratio = 2.91).
- A significant association was found between in utero Bendectin exposure and pyloric stenosis (odds ratio = 4.33), which persisted after controlling for confounding factors (odds ratios = 4.63-5.24).
- A possible link between Bendectin and heart valve anomalies was observed (odds ratio = 2.99), but other malformations were not significantly associated.
Conclusions:
- Maternal Bendectin use in early pregnancy may be associated with an increased risk of certain congenital malformations, notably pyloric stenosis.
- Maternal smoking appears to potentiate the teratogenic risk associated with Bendectin.
- Further research is warranted to fully elucidate the complex interplay between medication exposure, maternal characteristics, and developmental outcomes.